The Competition Commission of India (CCI) has recently given approval to the acquisition of Bharat Serums and Vaccines Ltd. by Mankind Pharma Ltd.

The proposed transaction involves the acquisition of 100 percent shareholding of Bharat Serums and Vaccines Ltd. (BSV) by Mankind Pharma Ltd.

Mankind is a publicly listed company and is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical finished dosage formulations (FDFs) across various acute and chronic therapeutic areas, as well as several consumer healthcare products such as condoms, emergency contraceptives, pregnancy tests, vitamins, minerals, nutrients, antacids and anti-acne preparations segments.

Through its subsidiaries, Mankind is also engaged in, inter alia, the manufacture and sale of active pharmaceutical ingredients (APIs), pharmaceutical intermediaries, and packaging products for pharmaceutical products.

BSV, along with its subsidiaries, is engaged in research, development, licensing, manufacturing, importing, exporting, marketing and distribution of (a) FDFs and APIs; (b) biotech and biological formulations and/or API; (c) food and health supplements; (d) medical devices; and (e) ayurvedic medicines; in each case, in the therapeutic areas such as gynecology, in-vitro fertilisation, critical care and/or emergency medicines for human use.

In India, the activities of BSV (including its wholly-owned Indian subsidiary, BSV Pharma Pvt. Ltd., which is in the process of merging with BSV) are limited to developing, manufacturing, and marketing a range of biological, biotech, and pharmaceutical products in the therapeutic areas of women’s health, critical care, IUI-IVF, and emergency medicine.